DMK Pharmaceuticals financials at a glance

+ Portfolio

The revenue of DMK Pharmaceuticals is reported as 0.00147 billion Dollars in the fiscal year 2023. The earnings were 0 Dollars per share in 2023, which was 15.99 lower than 2017. And about -0.01 billion Dollars are reported as free cash flow in the financials of DMK Pharmaceuticals 2023. No dividends were paid to the shareholders of the DMK Pharmaceuticals stock NasdaqCM:DMK in the financial year 2023.

Forecast

Financials

Year	Year	TTM	2018	2017	2016	2015	2014
Rev.	Revenue	N/A	$15.09M	$13.07M	$6.47M	$0.00M	$0.00M
GM %	Gross Margin %	-37.30%	35.06%	43.24%	25.03%	0.00%	0.00%
OM	Operating Margin	0.00%	-,261.51%	-,188.88%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-6.39	$-70.16	$-60.49	$-83.30	$-71.40	$-77.70
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	0	0	0	0	0
Sha.	Shares	N/AM	0.68M	0.48M	0.31M	0.19M	0.15M
OCF	Operating Cash Flow	N/A	$0.00M	$0.00M	$0.00M	$0.00M	$-6.78M
FCF	Free Cash Flow	N/A	$-36.19M	$-17.20M	$0.00M	$-10.34M	$-6.88M
FCFS	Free Cash Flow Per Share	$-2.70	$-0.93	$-0.61	$-1.22	$-0.78	$-0.83

DMK Pharmaceuticals financials at a glance

Financials

Discover